Development of Mycoplasma hyopneumoniae Recombinant Vaccines
Silvana Beutinger Marchioro1, Simone Simionatto2, Odir Dellagostin3
1Faculdade de Ciências da Saúde, Universidade Federal da Grande Dourados, Rodovia Dourados - Itahum, Km 12 - Cidade Universitaria, Cx. Postal 533, Dourados, MS, CEP 79804-970, Brazil.
Abstract:
Mycoplasma hyopneumoniae is the etiological agent of swine enzootic pneumonia (EP), a disease that affects swine production worldwide. Vaccination is the most cost-effective strategy for the control and prevention of the disease. Research using genome-based approach has the potential to elucidate the biology and pathogenesis of M. hyopneumoniae and contribute to the development of more effective vaccines. Here, we describe the protocol for developing M. hyopneumoniae recombinant vaccines using reverse vaccinology approaches.
Related Concept Videos
Vaccine Production
Microorganisms in Medicine and Therapeutics


